Please refer to our intimation under reg 30 of SEBI (LODR) Regulations, 2015 w.r.t. incorporation of wholly owned subsidiary in Japan.
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gujarat Themis Biosyn Limited has incorporated a wholly owned subsidiary named Themis Biosyn Japan Limited in Japan. The new company was incorporated on 19th May, 2026 with a share capital of Ten Lakhs Yen (10,00,000 Yen). The subsidiary operates in the pharmaceutical industry, consistent with the parent company's core business. Gujarat Themis Biosyn Limited holds 100% of the shareholding in the new entity. The business registration extract for the subsidiary is yet to be received.
This represents strategic international expansion into Japan, potentially opening new markets for the pharmaceutical company. However, the subsidiary is newly formed with no operational history or revenue yet, so immediate financial impact on the parent company is minimal.